Real-world outcomes with durvalumab after chemoradiotherapy in patients with unresectable stage III NSCLC: interim analysis of overall survival from PACIFIC-R
- Author(s)
- Filippi, AR; Bar, J; Chouaid, C; Christoph, DC; Field, JK; Fietkau, R; Garassino, MC; Garrido, P; Haakensen, VD; Kao, S; Markman, B; McDonald, F; Mornex, F; Moskovitz, M; Peters, S; Sibille, A; Siva, S; van den Heuvel, M; Vercauter, P; Anand, S; Chander, P; Licour, M; de Lima, AR; Qiao, Y; Girard, N;
- Details
- Publication Year 2024-06-03,Volume 9,Issue #6,Page 103464
- Journal Title
- ESMO Open
- Publication Type
- Research article
- Abstract
- BACKGROUND: Based on the findings of the PACIFIC trial, consolidation durvalumab following platinum-based chemoradiotherapy (CRT) is a global standard of care for patients with unresectable, stage III non-small-cell lung cancer (NSCLC). An earlier analysis from the ongoing PACIFIC-R study (NCT03798535) demonstrated the effectiveness of this regimen in terms of progression-free survival (PFS). Here, we report the first planned overall survival (OS) analysis. PATIENTS AND METHODS: PACIFIC-R is an observational/non-interventional, retrospective study of patients with unresectable, stage III NSCLC who started durvalumab (10 mg/kg intravenously every 2 weeks) within an AstraZeneca-initiated early access program between September 2017 and December 2018. Primary endpoints are OS and investigator-assessed PFS, estimated using the Kaplan-Meier method. RESULTS: By 30 November 2021, the full analysis set included 1154 participants from 10 countries (median follow-up in censored patients: 38.7 months). Median OS was not reached, and the 3-year OS rate was 63.2% (95% confidence interval 60.3% to 65.9%). Three-year OS rates were numerically higher among patients with programmed death-ligand 1 (PD-L1) expression on ≥1% versus <1% of tumor cells (TCs; 67.0% versus 54.4%) and patients who received concurrent CRT (cCRT) versus sequential CRT (sCRT) (64.8% versus 57.9%). CONCLUSIONS: PACIFIC-R data continue to provide evidence for the effectiveness of consolidation durvalumab after CRT in a large, diverse, real-world population. Better outcomes were observed among patients with PD-L1 TCs ≥1% and patients who received cCRT. Nevertheless, encouraging outcomes were still observed among patients with TCs <1% and patients who received sCRT, supporting use of consolidation durvalumab in a broad population of patients with unresectable, stage III NSCLC.
- Publisher
- Elsevier
- Keywords
- Pd-l1; durvalumab; immunotherapy; locally advanced NSCLC; real-world evidence
- Department(s)
- Radiation Oncology
- Publisher's Version
- https://doi.org/10.1016/j.esmoop.2024.103464
- Open Access at Publisher's Site
https://doi.org/10.1016/j.esmoop.2024.103464- Terms of Use/Rights Notice
- Refer to copyright notice on published article.
Creation Date: 2024-07-09 04:06:16
Last Modified: 2024-07-09 04:14:02